Skip to content
Research Article Open access CC BY 4.0

Study of Factor VIII Inhibitor and F8 Gene Mutations in Persons with Hemophilia A from Benin

Tatiana Baglo, Alban Zohoun, Bienvenu Houssou, Romaric Massi, Charlotte Orou Guiwa, Ludovic Anani, Dorothée Kindé Gazard, Awa Omar Touré Fall

International Blood Research & Reviews · pp. 38–44 · Published 1 Mar 2024

10.9734/ibrr/2024/v15i1333

Abstract

Aim: determine the prevalence of a FVIII inhibitors and identify the genetic mutations associated with their development in beninese personne with hemophilia (PwH) A. Study Design: this is cross-sectional descrptive study conducted from June 2022 to May 2023 in hemophilia treatment centers in Benin. Methodology: Inhibitor screening was carried out systematically in all PwHs A receiving FVIII infusion through determination of the circulating anticoagulant index and the Nijmegen-Bethesda assay. The molecular study strategy used for the F8 gene associated with hemophilia A is dependent on the severity of the hemophilia. Other data were collected either from patients' responses to the questionnaire or by studying their medical records and the center's hemophilia registry. Results: Of the 97 PwHs A followed up, 57 had been treated with FVIII infusion. Of these, 21 had developed inhibitors, representing a frequency of 36.8% of treated PwHs A and 43.75% of severe PwHs. None of the moderate or mild PwHs A had developed anti-FVIII antibodies. PwHs A with inhibitors had a median age of 11 years, ranging from 1 to 66 years.  The Nijmegen-Bethesda test revealed 11 high responders and 10 low responders. Mutation analysis of the F8 gene revealed seven cases of intron 22 inversion, seven cases of nonsense mutations, three cases of deletion and one case of missense mutation. Mutations weren’t identified in three patients because their DNA did not amplify on long-distance PCR.  In terms of therapy, immune tolerance induction wasn’t achieved in any of the 21 patients, but they are treated with emicizumab and bypass depending on the context. Conclusion: Although a cross-sectional study with a limited sample size, this study provides valuable information on beninese PwHs A with inhibitors. The frequency of inhibitors is high in treated PwHs A, and almost all patients who have developed inhibitors have high-risk genetic mutations.

Hemophilia A inhibitors Nijmegen-Bethesda test F8 gene variants genetics

References (21)

  1. 1 The epidemiology of inhibitors in haemophilia A: a systematic review [DOI]
  2. 2 The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation [DOI]
  3. 3 Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review [DOI]
  4. 4 The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99 [DOI]
  5. 5 Genetic risk factors for inhibitors to factors VIII and IX [DOI]
  6. 6 Inhibitors of Factor VIII in Black Patients with Hemophilia [DOI]
  7. 7 Risk factors for inhibitor development in severe hemophilia A [DOI]
  8. 8 Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update [DOI]
  9. 9 Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia [DOI]
  10. 10 Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies [DOI]
  11. 11 Factor VIII gene variants and inhibitor risk in African American hemophilia A patients [DOI]
  12. 12 Inhibitors – genetic and environmental factors [DOI]
  13. 13 Factor VIII inhibitors in haemophiliacs: a single‐centre experience over 34 years, 1964–97 [DOI]
  14. 14 Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients [DOI]
  15. 15 Inhibitor epidemiology and genetic‐related risk factors in people with haemophilia from Côte d’Ivoire [DOI]
  16. 16 The natural history of factor VIII inhibitors in patients with hemophilia A.
  17. 17 Factor VIII Inhibitors in Patients with Hemophilia A [DOI]
  18. 18 Molecular diagnosis of haemophilia A in patients from Senegal [DOI]
  19. 19 Prevalence of Factor VIII Inhibitors in Patients with Hemophilia A in Brazil [DOI]
  20. 20 Prevalence of inhibitor formation in a cohort of haemophilic children exposed to several products of various purities [DOI]
  21. 21 In silico study of correlation between missense variations of F8 gene and inhibitor formation in severe hemophilia A [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

63

Page views

0

PDF downloads

16

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.